Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just announced that it is carrying forward with a special protocol assessment (SPA) for its lead asset, Firdapse......
(read more)November 1 - News, Stock Analysis - Comments
Which are the most successful innovative companies in the world in 2016? Bringing something new to the table is something that seems to be difficult these......
(read more)October 26 - Hedge Funds, Lists, News - Comments
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) just put out an update relating to its lead achondroplasia asset, Vosoritide, and the company is up a couple......
(read more)October 20 - News, Stock Analysis - Comments
Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California. Prior to founding Blue Jay......
(read more)September 22 - Hedge Fund Analysis, Hedge Funds, News - Comments
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) just announced that the FDA has delayed its PDUFA for the companies lead Batten Disease candidate, meaning......
(read more)September 7 - News, Stock Analysis - Comments
The U.S stock market is green across the board as positive reigns ahead of crucial jobs data to be announced tomorrow. Some of the stocks that investors......
(read more)July 7 - Market Movers, News - Comments
Although crude futures are well in the green, the three indexes have opened in the red on Friday. The Dow and S&P 500 are off by 0.2% while the NASDAQ......
(read more)June 17 - Market Movers, News - Comments
Among some 800 hedge funds we track at Insider Monkey, we seldom come across funds that specialize in investing in a particular sector or have a penchant......
(read more)May 16 - Hedge Funds, News - Comments
William Leland Edwards‘ Palo Alto Investors has about $2.22 billion worth of regulatory assets under its management. According to our calculations......
(read more)March 2 - Hedge Funds, News - Comments
Palo Alto Investors, founded by Wall Street veteran William Leland Edwards in 1989, is one of the biggest healthcare investment shops in the United States......
(read more)December 1 - Hedge Fund Analysis, Hedge Funds, News - Comments
Kyle Bass of Hayman Advisors is one investment manager with great cachet, which includes having a chapter dedicated to him in Michael Lewis’ post......
(read more)December 1 - Hedge Fund Analysis, Hedge Funds, News - Comments
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) a good stock to buy now? Shares of the company are surging today after the pharmaceutical firm revealed......
(read more)June 18 - Hedge Funds, News - Comments
The broad portfolio of Jacob Gottlieb’s Visium Asset Management enjoyed a very strong quarter, with the weighted average returns of its 817 reported......
(read more)April 10 - Hedge Funds, News - Comments
John Griffin’s Blue Ridge Capital had a great start to the year, as its 45 long positions in stocks with a market cap above $1.0 billion returned 6.......
(read more)April 9 - Hedge Funds, News - Comments
Paul Orlin‘s Amici Capital has increased its exposure to Era Group Inc (NYSE:ERA), as a new filing with the Securities and Exchange Commission......
(read more)March 27 - Hedge Funds, News - Comments
ABIOMED, Inc. (NASDAQ:ABMD) spiked as high as 21% in Tuesday’s intraday trading to eventually close at 18% in the green at $72.48. The rise came......
(read more)March 25 - Hedge Funds, Market Movers, News - Comments
Jacob Gottlieb‘s Visium Asset Management has recently revealed its equity positions as of the end of the fourth quarter in a 13F filing with the......
(read more)March 3 - Hedge Funds, News - Comments
Tang Capital Management, led by Kevin C. Tang, revealed in a filing several moves that have impacted its equity portfolio. One of the companies involved......
(read more)January 16 - Hedge Funds, News - Comments
Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a good investment? If you were to ask many investors, hedge funds are viewed as delayed, outdated investment......
(read more)August 29 - News - Comments
The phrase “PDUFA date” is thrown around frequently when discussing biotech and pharma companies. PDUFA stands for the Prescription Drug User......
(read more)August 27 - News - Comments
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a buy? In the 21st century investor’s toolkit, there are tons of metrics market participants can......
(read more)August 26 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors: listen up. In the 21st century investor’s toolkit, there are tons of metrics shareholders can use......
(read more)August 26 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors are standing pat. In the 21st century investor’s toolkit, there are dozens of indicators investors......
(read more)August 26 - News - Comments
Should you be crazy about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)? In the financial world, there are dozens of gauges shareholders can use to analyze......
(read more)August 26 - News - Comments
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times. Although there are more......
(read more)August 23 - News - Comments
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is really beginning to heat up, and it’s offering investors......
(read more)August 16 - News - Comments
There are few times when your doctor or physician will utter the phrase, “I don’t know” to a patient, but when you’re dealing......
(read more)August 5 - News - Comments
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases......
(read more)August 1 - News - Comments
You may or may not have heard, but it’s earnings season again. Contrary to popular belief, earnings season does actually take a break for a few......
(read more)July 22 - News - Comments
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been growing so rapidly that the company has been the object of many takeover......
(read more)July 11 - News - Comments
Orphan drug companies are an exciting new class in the healthcare sector — with good and bad investment opportunities — let’s look at......
(read more)June 28 - News - Comments
Goldman Sachs Group Inc (NYSE:GS) recently hosted its 34th Annual Global Healthcare Conference on June 11 – 13 in Rancho Palos Verdes, CA. Healthcare......
(read more)June 18 - News - Comments
Late last year, Clovis Oncology Inc (NASDAQ:CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show......
(read more)June 10 - News - Comments
There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks......
(read more)April 19 - News - Comments
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech......
(read more)March 6 - News - Comments
Orphan drugs — medications meant for small patient populations with rare, dangerous diseases — can be a rewarding business for biotech firms......
(read more)February 22 - News - Comments
Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies......
(read more)February 19 - News - Comments
How many of us as investors want to identify companies that are pioneers in their industry? Is it possible to find commonality across sectors, which factors......
(read more)February 18 - News - Comments
